Table 3.

Primary and secondary endpoints

Authors	Primary endpoints			Secondary endpoints
		Placebo	Treatment		Placebo	Treatment
Amoli et al. (2015)	Pretreatment PE variation	10.8 ± 2.5 mm	10.4 ± 2.4	Echocardiographic PE follow-up Mild	48%	28.6%
	Post-treatment PE variation	6.7 ± 6 mm	6.92 ± 5.5 mm	Echocardiographic PE follow-up Moderate		24.5%
				Echocardiographic PE follow-up Minimal		24.5%
Bunge et al. (2014)*	PPS	62 (15.5%)	57 (13.5%)	Complicated PPS	13 (3.2%)	16 (3.8%)
	Fever	64 (16%)	56 (13.3%)	Pericardiocentesis/thoracotomy for tamponade	8 (2%)	11(2.6%)
	Pericardial rubbing	87 (21.7%)	102 (24.2%)	Evacuation for PE	4 (1%)	5 (1.2%)
				Readmission for PPS	8 (2%)	3 (0.7%)
Finkelstein et al. (2002)	PPS	14 (21.9%)	5 (10.6%)	Pericarditis	17 (27%)	6 (12%)
Imazio et al. (2010)	PPS at 12 months	38 (21.1%)	16 (8.9%)	Recurrence	2 (1.1%)	0
	Fever 1 po week	7 (3.9%)	6 (3.3)	Cardiac tamponade	1 (0.6%)	0
	Pleuritic chest pain	23 (12.8%)	7 (3.9%)	Constrictive pericarditis	0	0
	Friction rub	15 (8.3%)	5 (2.7%)	PPS-related hospitalization	6 (3.3%)	1 (0.6%)
	Pleural effusion	46 (25.6%)	22 (12.2%)
	New or worsening pericardial effusion	41 (22.8%)	23 (12.8%)
Imazio et al. (2014)	PPS within 3 months	53 (29.4%)	35 (19.4%)	PO AF	75 (41.7%)	61 (33.9%)
				PO pericardial /pleural effusion	106 (58.9%)	103 (57.2%)
				Cardiac tamponade	3 (1.7%)	1 (0.6%)
				Pericardiocentesis /thoracentesis	13 (7.2%)	13 (7.2%)
				PPS recurrence	3 (1.7%)	3 (1.7%)
				Disease-related readmission	2 (1.1%)	2 (1.1%)
				Overall mortality	2 (1.1%)	6 (3.3%)
				Stroke	1 (0.6%)	2 (1.1%)
Inan et al. (2011)**	Plural effusion (0–14 days)	5 (11.3%)	0	Pleural effusion (2–6 weeks)	3 (6.8%)	1 (2.4%)
Meurin et al. (2015	Pericardial effusion	1.1 ± 1.3 cm	1.3 ± 1.3 cm	Tamponade	7 (7%)	6 (6%)
				Mean effusion width change from baseline	4.7 ± 6.9 mm	5.8 ± 6.6 mm
				Echocardiographic grade decrease	66.7%	74.5%
				AF	12.1%	15.3%

^*Dexamethasone

^**indomethacin